Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity Disorder

NCT00419445 | Completed Phase 1 Results

• 1 other identifier: GTS21-202
• Study Type: interventional
• Target: 37
• Locations: 1 country
• Sites: 2

Brief Summary

This study will be a randomized, double-blind, placebo-controlled crossover study to assess the effects of GTS21 (25 mg three times a day (tid), 75 mg tid, 150 mg tid) compared to placebo in non-smoking adults aged 18-55 with a diagnosis of ADHD, any subtype.

Conditions

Attention Deficit Hyperactivity Disorder

Keywords

Attention Deficit Hyperactivity Disorder in adults

Outcome Measures

Primary Outcomes (1)

• To Assess the Safety and Tolerability of GTS21 (25 mg Tid, 75 mg Tid, 150 mg Tid).

  The proportion of subjects with Treatment Emergent Adverse Events.

  Baseline to study completion

Study Arms (3)

GTS21 25 mg tid/Placebo 25 mg tid

ACTIVE COMPARATOR

Drug: GTS21/Placebo

GTS21 75 mg tid/Placebo 75 mg tid

ACTIVE COMPARATOR

Drug: GTS21/Placebo

GTS21 150 mg tid/Placebo 150 mg tid

ACTIVE COMPARATOR

Drug: GTS21/Placebo

Interventions

GTS21/Placebo DRUG

GTS21 150 mg tid/Placebo 150 mg tid; GTS21 25 mg tid/Placebo 25 mg tid; GTS21 75 mg tid/Placebo 75 mg tid

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Male or female between the ages of 18-55, inclusive.
• Diagnostic and Statistical Manual for the Classification of Mental Disorders, Fourth Edition (DSM-IV) criteria for ADHD, any subtype, based on a detailed psychiatric evaluation including the Conners' Adult ADHD Interview for DSM-IV (CAADID) and the Structured Clinical Interview for DSM-IV (SCID).
• A minimum Total ADHD Symptoms Index score of 28 on the clinician administered CAARS.
• A Clinical Global Impressions-Severity (CGI-S) score of ≥ 4 at Screening.
• Normal or clinically insignificant ECG and clinical laboratory (e.g., liver enzymes, complete blood count, etc.) findings at Screening.
• Intellectual function at age-appropriate levels, as deemed by the Investigator.
• Supine systolic and diastolic blood pressure measurements \< 140 and \< 90, respectively, at Screening.
• Written, signed and dated informed consent for the patient to participate in the study must have been given by the patient.
• Females of child-bearing potential must have had a negative serum beta human chorionic gonadotropin (HCG) pregnancy test at Screening and be practicing double-barrier methods of contraception, if sexually active and for 30 days following administration of any study drug.
• Male patients who were sexually active must have agreed to use a reliable form of contraception during the study and for 30 days following administration of any study drug.
• Be fluent in English (speaking, writing and reading).

You may not qualify if:

• Any current, controlled (requiring a prohibited medication) or uncontrolled, comorbid psychiatric diagnosis (except simple phobias), all major depressive disorders \[dysthymia and mood disorder not otherwise specified (NOS) allowed unless medication required\],and any severe comorbid Axis II disorders or severe Axis I disorders such as Post Traumatic Stress Disorder, bipolar illness, psychosis, obsessive-compulsive disorder, substance abuse disorder, or other symptomatic manifestations that, in the opinion of the Investigator, contraindicated treatment with GTS21 or confound efficacy or safety assessments.
• Any condition or illness (including clinically significant abnormal laboratory values) which, in the opinion of the Investigator, represented an inappropriate risk to the patient and/or could confound the interpretation of the study.
• Regular use of nicotine products (including 90 days before Screening), including smoking, transdermal patch, chewing tobacco, etc. (verified via salivary cotinine levels at Screening).
• Current use of any prohibited medication or other medications, including herbal supplements, that have central nervous system (CNS) effects or affect cognitive performance, such as sedating antihistamines and decongestant sympathomimetics (bronchodilators were permitted).
• Use of another investigational product or participation in a clinical study within 30 days prior to Screening.
• Body Mass Index (BMI) \> 32.
• Known or suspected allergy, hypersensitivity, or clinically significant intolerance to nicotine or nicotinic agonists.
• Clinically important abnormality on urine drug screen (excluding the patient's current ADHD stimulant, if applicable) at Screening.
• Pregnant or currently lactating.
• Patients that had previously been enrolled into this study and subsequently withdrawn.

Sponsors & Collaborators

• CoMentis: lead

Study Sites (2)

George Washington University Medical Center

Washington D.C., District of Columbia, United States

Location

Duke University Medical Center

Durham, North Carolina, United States

Location

Related Links

• Related Info

MeSH Terms

Conditions

Attention Deficit Disorder with Hyperactivity

Interventions

3-(2,4-dimethoxybenzylidene)anabaseine

Condition Hierarchy (Ancestors)

Attention Deficit and Disruptive Behavior Disorders; Neurodevelopmental Disorders; Mental Disorders

Results Point of Contact

• Title: Carl Grove
• Organization: CoMentis (formerly Athenagen)

cgrove@comentis.com

650-869-7600

Study Officials

• Carl Grove

  CoMentis (formerly Athenagen)

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: GT60
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: January 4, 2007
• First Posted: January 8, 2007
• Study Start: February 1, 2007
• Primary Completion: January 1, 2008
• Study Completion: January 1, 2008
• Last Updated: September 10, 2010
• Results First Posted: September 10, 2010

Record last verified: 2010-08

Locations

US (2)